Loading organizations...
§ Private Profile · St Louis, MO, USA
Drug discovery company developing novel small molecule kinase inhibitors for autoimmune disorders, inflammation, and oncology.
Confluence Life Sciences was a St. Louis, Missouri-based clinical drug discovery company focused on developing novel kinase inhibitors for the treatment of autoimmune disorders, inflammation, and oncology. The enterprise specialized in small molecule therapeutics targeting specific diseases such as rheumatoid arthritis, psoriasis, and various cancers, utilizing a specialized research team with over 300 years of combined industry experience. Prior to its strategic exit, the firm secured early-stage financial backing and federal Small Business Innovation Research grant awards from regional investors including BioGenerator, the St. Louis Arch Angels, and the Missouri Technology Corp. In August 2017, the biotechnology company was officially acquired by clinical-stage biopharmaceutical firm Aclaris Therapeutics in a definitive transaction valued at approximately $100 million. Confluence Life Sciences was originally founded in 2009 by Joseph Monahan, Walter Smith, Jon Jacobsen, and Paul Changelian.
Confluence Life Sciences has raised $4.0M across 1 funding round.
Confluence Life Sciences has raised $4.0M in total across 1 funding round.
Confluence Life Sciences has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Series A in September 2012.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 17, 2012 | $4M Series A | Danny Janiak | Biogenerator, Helix Fund, Missouri Technology Corporation | Announced |
Confluence Life Sciences has raised $4.0M in total across 1 funding round.
Confluence Life Sciences's investors include Danny Janiak, BioGenerator, Helix Fund, Missouri Technology Corporation.